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Xenotropic-murine-leukemia-virus-related virus (XMRV) was the ﬁrst gammaretrovirus to be reported in humans. The sequence
similarity between XMRV and murine leukemia viruses (MLVs) was consistent with an origin of XMRV from one or more MLVs
present as endogenous proviruses in mouse genomes. Here, we review the relationship of the human and mouse virus isolates and
discuss the potential complications associated with the detection of MLV-like sequences from clinical samples.
1. Endogenous MLVs
Retroviruses are unique in their requirement, as a natural
step in their replication cycle, for integration into the gen-
omes of the host cells they infect [1]. Through infection of
the germ line, exogenous retroviruses can become a part of
the host genome, leading to the generation of endogenous
proviruses. All vertebrate species examined carry remnants
of such prior retroviral infections in their genomes [1, 2].
Humans, for example, carry some 80,000 sequences or about
8% of our total genome, derived from retrovirus infections
dating from some 40 million to a hundred thousand or so
years ago. Mouse genomes contain a large number of more
recently integrated endogenous proviruses; one of the best-
studied groups comprises the murine leukemia viruses
(MLVs). MLVs are thought to have entered the Mus germ
line less than 1.5 million years ago [3, 4], and generation of
new endogenous proviruses continues to this day. They can
be classiﬁed based on their host range and sequence into
ecotropic, xenotropic, polytropic and modiﬁed polytropic,
MLVs [1, 5]. The host range of MLVs is determined by
the species distribution of the receptors they use for entry.
Ecotropic MLVs (of which there are only a few) use mCAT1,
an allele of the cationic amino acid transporter found only
in mice and a few other rodents [6] .T h em o r ec o m m o n
nonecotropic MLVs, including xenotropic (X-MLV), poly-
tropic (P-MLV), and modiﬁed polytropic (MP-MLV) viruses
use distinct alleles of Xpr1, a cell surface protein of unknown
function, with X-MLVs unable to recognize the allele found
in most inbred and a few wild mice, hence the name “xen-
otropic” (reviewed in [7]). The proviruses that correspond
to these diﬀerent viruses are referred to as Xmv, Pmv,a n d
Mpmv, respectively. Experimentally, they are distinguished
by hybridization to oligonucleotide probes speciﬁc for a
sequence in the SU region of env. P-MLVs can be distin-
guished from MP-MLVs by a 27bp insertion in their env
genes [1, 5]. Endogenous nonecotropic proviruses are highly
polymorphic in their genome location: inbred mice contain
about 20 of each type and, on average, share about 30
with any other inbred strain. Of the 150 or so identiﬁed
proviruses, only a few Xmvs, including Bxv1 (Xmv43), are
known to encode infectious virus [8]. No complete, replicat-
ing P-MLV or MP-MLV has ever been identiﬁed, although
their env genes are often found as recombinants [1, 9].
As is the case with most host-pathogen arms races, evo-
lution at the host-virus interface for MLVs and their mouse
hosts is apparent on multiple levels. Xmv proviruses are
considered to be the oldest MLV subgroup, a hypothesis sup-
ported by the genetic diversity among members, their failure
to form a monophyletic clade, and their ancestral location
in phylogenetic analyses (Figure 1)[ 10]. During the long
course of their coexistence with endogenous and exogenous2 Advances in Virology
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Figure 1: Relationship of proviruses in the sequenced mouse genome. The three groups of nonecotropic MLVs are indicated. Modiﬁed from
Jern et al. [10].
MLVs, many Mus subspecies have evolved ways to cope with
such assaults. One example of a resistance mechanism is
the evolution of variants of the Xpr1 receptor so that the
modiﬁed allele no longer supports virus entry, conferring a
selective advantage on the host that carries the new variant.
Endogenous X-MLVs derived from proviruses in those mice
could not infect the cells of their host organism. Viruses have
in turn responded by incorporating mutations in their env
genes, allowing them to use the new version of the receptor
and giving rise to the evolution of polytropic and modiﬁed
polytropic MLVs, which are also carried in numerous
copies by many mouse genomes (Figure 2). Another level of
resistance is encoded by a set of proteins induced as result
of the expression of interferon (reviewed in [11]). One of
the most important of these is the enzyme family APOBEC3
A-G (in humans) with one homolog in mice, Apobec3.
APOBEC3’sareincorporatedintovirionsandcausehighlev-
els of dC to dU deamination on newly synthesized negativeAdvances in Virology 3
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Figure 2: Schematic cartoon of the hypothetical origin of X-MLV,
P-MLV,andXMRV.ThemiceillustratetheinferredpatternofMLV-
host evolution, starting with infection of mice with an exogenous
XMLV, its endogenization, selection for the resistant (Xpr1n)
receptor allele, and the subsequent evolution of the polytropic (P-
MLV and MP-MLV) viruses capable of using the mutant receptor.
strand DNA, leading to substantial frequencies of G to A
hypermutation in the positive strand (genome) of many
retroviruses, eﬀectively killing the provirus.
2. Origin of XMRV
Evidence for the presence of XMRV and other MLV-related
viruses in human tissues have so far relied on various
methodsincludingﬂuorescenceinsituhybridization(FISH),
immunological detection of viral antigens and antibodies
against them, isolation of infectious virus from human sam-
ples, and, ﬁnally, PCR ampliﬁcation of MLV sequences [12–
14]. We will discuss here only the last two issues, focusing on
the relationship of XMRV and related sequences to endoge-
nous MLVs and the likely events that gave rise to them. By
the term “XMRV,” we refer only to the infectious viruses
reported in the original papers [12,13,15]; related sequences
detected by PCR ampliﬁcation [14]w i l lb er e f e r r e dt oa s
“MLV-like” (Figure 1). We ﬁrst focus on XMRV.
XMRV was originally described in a fraction of prostate
cancer cases [12] and subsequently in a large fraction of
patientswithchronicfatiguesyndrome(CFS)[13].Theasso-
ciation of XMRV with disease rapidly became controversial,
however, when a large number of the studies in multiple
patient cohorts, prompted by the initial reports, did not ﬁnd
XMRV, even though very sensitive detection methods were
used (reviewed in [16]). The ensuing debate raised the issue
of whether, on the one hand, the negative studies reﬂected
poor technique or inappropriate study cohorts, or on the
other, the positive results reﬂected contamination with a
virus that did not, in fact, circulate in humans.
In contrast to most other irreproducible reports of
human“rumor”virusesdatingbacktothe1970s,XMRVwas
isolated as an infectious virus and grows to high titer on suit-
able human cell lines, from both diseases [13, 17]. An essen-
t i a l l yi d e n t i c a lv i r u sw a sa l s of o u n dt ob ep r o d u c e di nl a r g e
amounts by the 22Rv1 cell line [15], which had been derived
from a human prostate cancer by repeated passage, over the
course of 7 years, in the form of xenografts, in nude mice
(Figure 3)[ 18]. This result was interpreted to imply that the
tumor that eventually gave rise to the cell line was infected
with XMRV at the outset.
XMRV shows high sequence similarity to endogenous
Xmv proviruses [12], suggestive of a shared origin, but it
is not identical to any of them. Despite considerable eﬀort,
we did not ﬁnd it as a single endogenous provirus in any
mouse genome [19]. However, the fortunate availability of
DNA samples from various passages of the tumor xenografts
from which 22Rv1 had been derived made it possible to trace
the origin of XMRV [19]. Analysis of DNAs from early and
late passages revealed that the virus was undetectable (less
thanabout1provirusper200cells)insamplestakenthrough
1993, showing that the original tumor did not contain
XMRV (Figure 3). However, it was present in the xenografts
performed after 1996, suggesting that the tumor had been
infected by XMRV while being passaged through nude mice
some time between 1993 and 1996. Moreover, two XMRV-
related proviruses (PreXMRV-1 and -2) could be detected
in the small amount of mouse DNA in the tumor samples,
showing that the mouse strains used for the xenografts
contained these two previously undescribed proviruses,
whosegenomescouldrecombinetogenerateavirusvirtually
identical to XMRV (Figure 4), providing the most likely
explanation of how, where, and when the virus was created
[19]. Retrovirus recombination is a very frequent event that
occurs following infection of a cell with a virion containing
two distinct genomes, produced by a cell containing the two
parental proviruses. During the course of reverse transcrip-
tion, the enzyme transfers repeatedly from one genome to
the other, on average 4 times in the case of MLVs [20].
In the case of XMRV, a virion containing the PreXMRV-1
and PreXMRV-2 genomes and most likely containing pro-
teins made by both proviruses and produced by a cell of
the mouse host would have infected a human cell in the
xenograft, leading to the infectious XMRV recombinant. The
virus generated in this way could then spread through the
tumor, perhaps conferring some selective advantage (such
as increased growth rate or hormone independence) to the
infectedcells.Giventhelargenumberofstretchesofidentical
sequence in the two parental proviruses, the probability of4 Advances in Virology
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Figure 3: Derivation of the 22Rv1 cell line from prostate cancer xenografts in nude mice. Starting in 1992, the CWR22 prostate cancer was
passaged repeatedly in nude mice until 1999, when the cell line was isolated. Samples of the tumor prior to 1996 were negative for XMRV,
but contained small amounts of mouse DNA harboring both PreXMRV-1 and -2. Later samples were also positive for XMRV. Modiﬁed from
Paprotka et al. [19].
generating exactly the same recombinant more than once
independentlyisnegligible. Theseﬁndingsleadinexorablyto
the conclusion that the XMRV produced by 22Rv1 cells was
created in the laboratory (or, more likely, the mouse room)
and all subsequent isolates are likely to have originated from
this single unique recombination event, almost certainly by
cross-contamination in laboratories handling 22Rv1 cells
and other susceptible cell lines.
As mentioned above, xenotropic MLVs typically cannot
use the nonpermissive Xpr1n receptor variant carried by
most inbred strains [7]. When they encounter a permissive
c e l lt y p e ,h o w e v e r ,a sh a p p e n sw h e nh u m a nc e l l sa r et r a n s -
planted into mice, they can infect the cells of this newly
encountered species. Acquisition of mouse endogenous
retroviruses by heterologous cells occurs frequently, and
many examples have been documented [9, 21–24]. Thus,
the infection of the prostate cancer xenograft by an X-MLV
in mice was far from unprecedented, but the details of the
process, including the speciﬁc proviruses involved, had never
before been worked out.
In the decade following its derivation in 1999 [18], the
22Rv1 cell line has been distributed worldwide and widely
used for studies on prostate cancer biology. At the time of
this publication, PubMed listed over 200 papers reporting its
use from many diﬀerent laboratories, none of which could
have been aware before 2009 that it was producing 109–
1010 of virions per mL [15]. Given the ease with which
viruses can spread from one culture to another even in
virology laboratories that are aware of the problem, it is not
hard to see how XMRV could have contaminated cultures
in many diﬀerent laboratories. Such contamination not
only can give rise to false associations with human disease,
but also, cause major changes in cellular processes, leading
to alterations in cellular pathways under study. For these
reasons, it is absolutely necessary, and should be routine
practice, to continuously monitor cell lines for contaminat-
ing retroviruses.Advances in Virology 5
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Figure 4: Recombination between PreXMRV-1 and -2 leads to XMRV. The sequences of the two proviruses identiﬁed by Paprotka et al. are
shown schematically, with a vertical line indicating each position that diﬀers from the XMRV consensus. The red line shows the positions
of the 6 crossover events (common during retrovirus replication) that are inferred to have given rise to a virus diﬀering from XMRV at only
the 4 positions shown. Modiﬁed from Paprotka et al. [19].
Phylogenetic analysis of XMRV isolates in comparison
with endogenous MLVs also strongly supports the same
series of events. As can be seen in Figure 5,P r e X M R V - 1
groups with another Xmv subclade; PreXMRV-2 (which may
itself be a recombinant) is closer, but not identical, to Pmvs.
In the enlarged portion of the tree representing all published
XMRV isolates, it can be seen that the inferred recombinant
virus occupies a position ancestral to all XMRVs, followed by
the virus produced by 22Rv1 cells, followed by the prostate
cancer isolates, and followed ﬁnally by the CFS isolates,
exactlyconsistentwiththeinferredsequenceofinfectionand
contamination events [19].
The two XMRV parents are not unique to nude mice: of
48 laboratory mouse strains tested, PreXMRV-1 is found in
6, PreXMRV-2 in 25 [Cing¨ oz et al. In prep.], as well as in the
NIH3T3 cell line, commonly used for many laboratory pur-
poses,includingpreparationofMLV-basedgenetherapyvec-
tors [25]. Three laboratory strains, including the two nude
mice presumably used to passage the original tumor, contain
both proviruses. They are also found in DNA from some
wild-derived mice: PreXMRV-1 in M. m. molossinus and M.
m. castaneus,a n dP r e X M R V - 2i nM. m. domesticus. Since
the former mice are native to Asia, and the latter to Europe,
it is improbable that they were ever together in the wild
before human intervention.
In further support of the idea that XMRV has not
infected humans is its high sensitivity to the primate
APOBEC3G restriction factor, an interferon-inducible pro-
tein, which is constitutively expressed in some (but not all)
cell types. Indeed, the extensive hypermutation caused by
A3G makes it impossible to establish spreading infection
of human PBMCs in cell culture [26] and, while proviral
DNA persists in macaques experimentally infected with
XMRV, this DNA is also heavily hypermutated [Kearney et
al. In prep.]. Unlike PBMCs, a number of human cell lines,
including the prostate cancer lines 22Rv1 and LNCaP do
not express APOBEC3G. Combined with a favorable tran-
scriptional environment [17], this property makes these cells
particularly good hosts for XMRV infection, so it is not
impossible that the virus could sometimes bypass the barrier
to infect of blood cells.
3. MLV-Like Sequences
In an attempt to replicate the ﬁndings of XMRV in CFS
patients, Lo et al. analyzed plasma and PBMCs from another
cohort of CFS patients as compared to samples obtained
at a diﬀerent time and place from normal blood donors
[14]. They reported that they were unable to detect XMRV
using a speciﬁc PCR assay, but that, with somewhat less
selective primers, they could detect fragments of sequence
identical or closely related to some endogenous P-MLVs
and MP-MLVs. Again, the sequences were detected much
more frequently in samples from CFS patients than from the
poorly matched controls. The close match of these sequences
to endogenous MLVs present in over 100 copies per cell in
laboratory and wild mice immediately raised the possibility
of contamination of the samples with traces of mouse DNA.
To counter this concern, Lo et al. also tested the samples
formousemitochondrialDNAand,ﬁndingnone,concluded
that the results reﬂected infection of the patients, but not
the controls, with polytropic-like MLV. In further support of
this conclusion, they reported, that later samples from some
of the same patients also contained MLV-like sequences.
These sequences showed genetic diﬀerences from the earlier
ones, leading them to conclude that there was ongoing virus
replication and evolution.
The possibility of a human gammaretrovirus circulating
among the population and potentially having an association
with human disease created considerable excitement in the
ﬁeld. A number of researchers proposed that XMRV- and
MLV-related sequences represented related ﬁndings that6 Advances in Virology
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Figure 5: Phylogenetic analysis of MLVs and XMRV isolates. Note the positions of the two parents. The enlarged inset shows the XMRV
portion of the tree, illustrating the ancestral position of the inferred recombinant and the subsequent possible progression of the virus. From
Paprotka et al. [19].
stronglysupportedtheconclusionoftheassociationofMLV-
likeviruseswithhumandisease.However,oneshouldbevery
cautious about associating the two observations. Xenotropic
and polytropic viruses are distinct MLV subclasses, a fact
readily observed upon comparing the positions they occupy
in phylogenetic trees [10] (Figures 1 and 5). XMRV is not
found as a single endogenous provirus in any mouse strain
tested [19], whereas the partial sequences detected by Lo
et al. are very close or identical to proviruses found in
mice [14]. XMRV sequences detected by Lombardi et al.
are nearly identical to the XMRV sequences described by
Urisman et al. and form a distinct clade among Xmv
proviruses,whiletheMLV-likesequencesofLoetal.foundin
CFS and control samples are dispersed among other mouse
endogenous proviruses [12–14]( Figure 6). The reported
MLV-like sequences are bulk PCR fragments; no full length
viral genome or infectious virus was recovered, as opposed
to the Lombardi et al. study where infectious virus was
recovered upon culturing patient samples. P-MLV fragments
were detected following high numbers of PCR ampliﬁcation
cycles; no other detection methods were used and the results
havenotbeenreplicatedbyanyotherstudypublishedtodate.
The diﬀerences between the two studies in the experimental
methods used and the ﬁndings reported call for extreme
caution to be taken before widely interpreting the data.
Until we have a better understanding about the relationship
between these viruses, the two studies should be treated
separately and should not be taken as supporting or refuting
each other.
Despite the inclusion of apparently adequate controls,
mouse DNA contamination remains a signiﬁcant concern.
Extremely small amounts of DNA, from as little as one one-
hundredth of a cell, contain enough provirus sequences to
yield false positives with internal provirus-speciﬁc primers
(Figure 6, middle panel). Two recent studies have described
thedetectionofMLV-likesequencesinsamplesfrompatients
and/or healthy controls. In the ﬁrst study by Oakes et al.,
positive ampliﬁcation results were obtained from only 1 out
of 111 samples tested from CFS patients, but from 18/36
healthycontrols,whichhadbeenprocessedatadiﬀerenttime
with a slightly diﬀerent protocol [27]. In the second study,
Robinson et al. found that 14/282 of UK prostate cancer
cases, 5/139 of Korean, and 2/6 of Thai cases tested positive
for ampliﬁcation with XMRV primers [28]. As with the Lo
et al. sequences, those of Oakes and Robinson ﬁt perfectly
withintheendogenousMLVphylogeny(Figure 6,leftpanel).
In both cases, some, but not all, MLV-positive samples were
also positive for mouse mitochondrial DNA. To improve the
sensitivityofdetectionofmouseDNA,wedevelopedanassay
thatreliesonPCRampliﬁcationofasmallfragmentfromthe
LTR of intracisternal A particles (IAPs), LTR retroelements
that are abundant (more than 1000 copies) in the mouse
genome and not cross-reactive with any sequence in the
human genome despite the presence of distantly related IAP
elements [29]. Using this assay, both studies found that
all samples that tested positive for MLV DNA sequences
were also positive for IAP LTR sequences, implying sporadic
mouse DNA contamination as the most likely source of theAdvances in Virology 7
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formersequences.Theexactsourceofthesemousesequences
has not fully pinned down. Trace amounts of mouse DNA
could be already present in the laboratory reagents used or
contaminationcouldhaveoccurredduringsamplecollection
or storage before they were even sent to the laboratories to
be tested for XMRV. Four other studies further supported
these ﬁndings, where potential sources of MLV genome
contaminants, most likely from mouse genomic DNA, were
discovered in commercially available laboratory reagents
and kits, particularly Taq DNA polymerase containing a
mouse monoclonal antibody [30–33]. It is possible that
microtomes used for both laboratory and clinical samples
could carry traces of mouse DNA over to human pathology
samples, perhaps including the ﬁxed and archived prostate
cancer specimens analyzed by Robinson et al. [28]. Cross-
contaminationfromalaboratoryrobotusedforXMRVmore
than a year previously has also been reported [33]. Taken
together, these ﬁndings call for caution before interpreting
thedataandtheneedforverysensitiveassaystodetectmouse
DNA contamination, when endogenous MLV sequences are
detected by PCR from human samples.
It is also important to emphasize that considerable cau-
tion should be exercised when attributing the origin of short
PCR amplicons to a replicating virus, when the virus has
itself not been isolated. Indeed, for reasons that are unclear,
replication-competent P-MLVs have never been identiﬁed
in mice, although their envelope genes can be donated to
replication-competent recombinant viruses that arise and
cause lymphoma in some strains of mice [35–37]. Until a
real virus is identiﬁed, studies reporting detection of “virus”
sequences must be taken as highly preliminary and sugges-
tive,notdeﬁnitive,evidenceforhumaninfectionbyP-MLVs.
A ﬁnal problem with the sequences reported by Lo et al.
is that they do not exhibit the sort of evolution expected for
long-term infection. Although these authors reported that
sequences that appeared to show evolutionary changes were
obtained from some of the same patients ∼15 years after
the initial sampling [14], examination of the sequences made
available in the GenBank database reveals that the “evolved”
sequences are in fact very similar to other endogenous
MLVs. (Figure 6, right panel) [27]. Rather than evolving as
would be expected of a true infecting virus, these sequences8 Advances in Virology
therefore seem to be simply moving up and down the MLV
phylogenetic tree. The conclusion that they represent MLV
sequences ampliﬁed from trace mouse DNA contamination
is inescapable.
4. ParticularIssues regardingDetectionof
MLVs as Possible HumanPathogens
The initial reports of association between endogenous MLV-
related viruses and human disease were attractive because
of their biological plausibility: MLV-related viruses cause a
similar variety of diseases in mouse models [1]; close contact
between mice and humans can result in zoonotic infection;
the virus isolated is highly infectious for at least some
human tumor cell lines [17, 38]. As the studies presented
here unfolded, however, a number of experimental issues
regarding the possibility of detection of endogenous proviral
sequencesandtheirconfusionwithreplicatingvirusesinfect-
ing human patients came to light. There are a number of
lessons that should be heeded in the development of future
studies.
First, low levels of mouse DNA contamination are very
commonly found in laboratory reagents. In some cases, this
DNA can be attributed to the inclusion of mouse-derived
products, such as monoclonal antibodies in PCR reagents,
or used for isolation of cells [27, 28, 30, 32, 33]; in others, the
source of mouse DNA is less than clear, but given the close
relationship of human and wild mouse activity, it is not hard
to imagine that mice can leave traces in many places that can
ﬁnd their way into almost any laboratory reagent or supply.
A second, related issue regards the provision of appropri-
ate controls. Given the apparent sporadic nature of this sort
of contamination, it is absolutely essential that controls and
patient samples be exactly matched, not only for personal
characteristics, such as age, gender, geography, and so forth,
but also in the reagents and materials (tubes, needles, etc.)
used to obtain and process the assay samples. Unfortunately,
such caution is often not the case, particularly in retro-
spective studies [14]. Clinical samples are often collected
as at least two separate groups, the simplest example being
patientversuscontrolsamples.Thislackofcautioncanresult
in detection of a contaminant in one set of samples and not
the other, resulting in false association of virus with human
disease.Diﬀerentialassociationbetweentwodiﬀerentgroups
of clinical specimens can occur, even if the detected entity
is an artifact. In fact, in the study by Oakes et al. [27],
MLV sequences were detected preferentially in healthy
controls drawn at a later time and processed by a slightly dif-
ferent method. One possible explanation for such erroneous
associations is that the two groups might have been handled
diﬀerently, collected at diﬀerent times by diﬀerent people
at diﬀerent locations using diﬀerent reagents, supplies, or
methods. Furthermore, tubes containing patient samples
may have been accessed more frequently and under diﬀerent
circumstances than controls. For these reasons, blinding
of investigators to which samples are cases and which are
controls for such studies is crucial. Examples of such false
associations have persisted, even when independent labora-
tories had conﬁrmed ﬁndings after the initial report [39].
Third,evenintheabsenceofcontaminatingmouseDNA,
adiﬀerentcomplicationarisesfromretrovirus-contaminated
cell lines used in the laboratory. There are multiple docu-
mented cases of such contamination events, which appear
to be quite common among laboratories working with
retroviruses [8, 15, 40–43]. Even in laboratories that do not
work with retroviruses, there are examples of cell lines pro-
ducing replication-competent retroviruses. Contamination
of cell lines with retroviruses could occur through cross-
contamination of previously uninfected cells with a virus
grown or handled on other cells nearby. As long as the
virus is replication-competent and can establish an eﬃcient
infection,it couldeventuallytakeoverthe entire cultureeven
with trace amounts of starting virus.
The overalllesson tobe learned hereis thatextrememea-
suresarerequiredtoavoidfalseassociationsofmouseviruses
with disease, including: (1) rigorous use of highly sensitive
assays for detecting mouse DNA contamination of supplies
and reagents; (2) frequent testing of cell cultures used in the
laboratory for undetected infection with an MLV or another
virus; (3) the use of controls that are exactly contempo-
raneous to the cases and obtained by precisely the same
methods using the same materials and reagents. As a few
recent papers indicate [30, 32, 33], these conditions are not
easy to achieve, but only laboratories that do so can make
credible claims to the discovery of new human infections.
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